Verona Pharma plc Verona Pharma Plc : Block Listing Interim Review
01 December 2017 - 5:52AM
UK Regulatory
TIDMVRP TIDMVRP
LONDON, Nov. 30, 2017 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP)
(Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical
company focused on developing and commercializing innovative therapies
for respiratory diseases, provides the following update on its block
listing, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for
Companies, regarding its existing block listing arrangements, put in
place from 29 July 2016:
Name of applicant: Verona Pharma plc
Name of scheme: 2016 Warrant
Shares
Period of return: From 3 May 2017
to 30 November
2017
Balance of unallotted securities under scheme(s) from 12,446,370
previous return: Ordinary Shares
of 5 pence each
Plus: The amount by which the block scheme(s) has Nil
been increased since the date of the last Review (if
any increase has been applied for):
Less: Number of securities issued/allotted under scheme(s) Nil
during period
Equals: Balance under scheme(s) not yet issued/allotted 12,446,370
at end of period: Ordinary Shares
of 5 pence each
Number and class of share(s) (amount of stock/debit 10,262,879 on 29
securities) originally admitted and the Date of Admission: July 2016
Name of contact: Claire Poll
Telephone number of contact: +44 (0)20 3283 4200
For further information, please contact:
Verona Pharma plc Tel: +44 (0)20 3283 4200
Jan-Anders Karlsson, Chief Executive Officer info@veronapharma.com
Stifel Nicolaus Europe Limited (Nominated Adviser Tel: +44 (0) 20 7710 7600
and UK Broker) SNELVeronaPharma@stifel.com
Stewart Wallace / Jonathan Senior / Ben Maddison
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on
developing and commercializing innovative therapies for the treatment of
respiratory diseases with significant unmet medical needs.
Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled,
dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as
both a bronchodilator and an anti-inflammatory agent in a single
compound. Verona Pharma is developing RPL554 for the treatment of
chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF),
and potentially asthma.
Verona Pharma's shares are traded on the London AIM market under the
symbol VRP.L. Further information on Verona Pharma can be found at
http://www.veronapharma.com/
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Verona Pharma plc via Globenewswire
http://www.veronapharma.com/
(END) Dow Jones Newswires
November 30, 2017 13:52 ET (18:52 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
Verona Pharma (LSE:VRP)
Historical Stock Chart
From Apr 2024 to May 2024
Verona Pharma (LSE:VRP)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Verona Pharma Plc (London Stock Exchange): 0 recent articles
More Verona Pharma News Articles